The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 7, 2008, Pages 1367-1376

  Van Laere, Koen ^a   Everaert, Ludwig ^b   Annemans, Lieven ^c   Gonce, Michel ^d   Vandenberghe, Wim ^a   Vander Borght, Thierry ^e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Medical and Pharmaceutical Information ^*  (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

123I FP CIT; Clinical impact; Dopamine transporter; Pharmaco economic modelling

Indexed keywords

AMANTADINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; IODINE 123; ISOTOPE; LEVODOPA; N OMEGA FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE; NEUROPROTECTIVE AGENT; SELEGILINE; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; TROPANE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DYSKINESIA; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PREDICTIVE VALIDITY; PROBABILITY; PSYCHOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATONIGRAL DEGENERATION; UNCERTAINTY; BELGIUM; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; METABOLISM; MULTICENTER STUDY; SCINTISCANNING; STATISTICAL MODEL; VALIDATION STUDY;

BELGIUM; COST-BENEFIT ANALYSIS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; IODINE RADIOISOTOPES; MARKOV CHAINS; MODELS, ECONOMIC; PARKINSONIAN DISORDERS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 45049084405     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0777-2     Document Type: Article

References (23)

1. Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001;28:266-72.
2. Lokkegaard A, Werdelin LM, Friberg L. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med Mol Imaging 2002;29:1623-9.
3. Eerola J, Tienari PJ, Kaakkola S, Nikkinen P, Launes J. How useful is [123I]beta-CIT SPECT in clinical practice? J Neurol Neurosurg Psychiatry 2005;76:1211-6.
4. Hesse S, Oehlwein C, Barthel H, et al. Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome. J Neural Transm 2006;113:1177-90.
5. Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000;15:503-10.
6. Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004;19:1175-82.
7. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005;64:208-15.
8. Dodel RC, Hoffken H, Moller JC, et al. Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach. Mov Disord 2003;7(18 Suppl):S52-62.
9. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999;28:99-102.
10. Andersen PK, Keiding N. Multi-state models for event history analysis. Stat Methods Med Res 2002;11:91-115.
11. Cooper K, Brailsford SC, Davies R, Raftery J. A review of health care models for coronary heart disease interventions. Health Care Manag Sci 2006;9:311-24.
12. Koch W, Hamann C, Radau PE, Tatsch K. Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism? Eur J Nucl Med Mol Imaging 2007;34:1265-73.
13. Tanner CM, Hubble JP, Chan P. Epidemiology and genetics of Parkinson's disease. In: Watts RL, Koller WC, editors. Movement disorders. New York: McGraw-Hill; 1997. p. 137-52.
14. Seibyl JP, Marek K, Sheff K, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 1998;39:1500-8.
15. Van Laere K, De Ceuninck L, Dom R, et al. Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1. Eur J Nucl Med Mol Imaging 2004;31:1119-27.
16. Acton PD, Newberg A, Plossl K, Mozley PD. Comparison of region-of-interest analysis and human observers in the diagnosis of Parkinson's disease using [99mTc]TRODAT-1 and SPECT. Phys Med Biol 2006;51:575-85.
17. Chou KL, Hurtig HI, Stern MB, et al. Diagnostic accuracy of [99mTc]TRODAT-1 SPECT imaging in early Parkinson's disease. Parkinsonism Relat Disord 2004;10:375-9.
18. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6:305-13.
19. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism-a prospective study. Can J Neurol Sci 1991;18:275-8.
20. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
21. Jankovic J. Essential tremor: clinical characteristics. Neurology 2000;54:S21-5.
22. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-91.
23. Beyer MK, Herlofson K, Arsland D, Larsen JP. Causes of death in a community-based study of Parkinson's disease. Acta Neurol Scand 2001;103:7-11.